Ivermectin is one of the more precisely weight-calibrated drugs in general use, and that precision is not incidental. This article explains how clinicians actually arrive at an ivermectin dose, why the calculation is built on body weight rather than age or a fixed pill count, what the approved dosing charts look like, and where the evidence is solid versus where it is thin. The goal is to give you the same reasoning your physician or pharmacist would use, so that any dosing decision happens in partnership with them rather than from a chart alone.

What Ivermectin Is Approved to Treat

Ivermectin is an antiparasitic medication derived from avermectins, compounds isolated from a soil bacterium, Streptomyces avermitilis, discovered in Japanese soil samples in the 1970s by microbiologist Satoshi Ōmura and later developed with parasitologist William Campbell at Merck. Their work earned the 2015 Nobel Prize in Physiology or Medicine, and it is worth pausing on the fact that a drug now used to protect millions of people from blinding and debilitating parasitic disease was found in ordinary dirt. It is a reminder that the created world holds resources we are still discovering, and that careful, patient science remains the right way to bring them to patients safely.

In the United States, oral ivermectin (brand name Stromectol, and generic equivalents) is FDA-approved for two conditions: intestinal strongyloidiasis (a roundworm infection) and onchocerciasis, also called river blindness, caused by the parasite Onchocerca volvulus. Topical ivermectin formulations are separately approved for rosacea and head lice. It is not FDA-approved for any viral illness, including COVID-19, and it is not approved as a general-purpose "dose it and see" medication. Any use outside these approved indications is off-label, meaning a physician may still prescribe it using clinical judgment, but it has not gone through the same regulatory review for that purpose.

The Core Principle: Micrograms Per Kilogram, Not a Flat Pill Count

Unlike medications that come in a single standard adult dose, ivermectin is dosed on a milligram-per-kilogram (or more precisely, microgram-per-kilogram) basis. For strongyloidiasis, the approved single dose is 200 micrograms per kilogram of body weight (0.2 mg/kg). For onchocerciasis, it is 150 micrograms per kilogram (0.15 mg/kg), often repeated every 3 to 12 months depending on ongoing exposure risk. This means a 50-kilogram adult and a 90-kilogram adult are never meant to take the same number of milligrams, even though many other drugs on the pharmacy shelf are dosed that simplistically.

This is precisely why questions like "how much should I take" cannot be answered with a single number. The honest answer is always: it depends on your weight, the condition being treated, and your physician's assessment of your kidney and liver function, other medications, and overall health.

The Actual Weight-Based Dosing Charts

Because ivermectin tablets come in fixed strengths, prescribing information translates the mg/kg target into a practical tablet count across weight bands. In the United States, tablets are manufactured in 3 mg strength. The FDA-approved chart for strongyloidiasis, using single-dose 3 mg tablets, is structured approximately as follows:

The onchocerciasis chart uses the lower 150 mcg/kg target and shifts the weight bands slightly, typically running from a single 3 mg tablet around 15–25 kg up to 12 mg around 65–84 kg, with direct calculation above that. Outside the US, 12 mg tablets are common, and in some countries scored tablets or combination strengths are used for scabies, other helminth infections, or mass drug administration campaigns for river blindness. A 12 mg tablet is simply a different unit size for delivering the same underlying mg/kg target; it does not represent a different dosing philosophy. Whatever the tablet strength, the arithmetic works backward from body weight, not forward from the pill.

For scabies, a common off-label oral regimen is two doses of 200 mcg/kg given about a week to two weeks apart, because the drug does not reliably kill mite eggs, and a second dose catches newly hatched mites. This is a judgment made by a treating clinician, not a fixed universal schedule, since scabies treatment often also involves topical agents and treatment of household contacts.

Why the Body's Weight, Specifically, Drives the Number

Ivermectin is lipophilic, meaning it dissolves readily into fat and distributes through the body's tissues in proportion to overall body mass rather than staying concentrated in the bloodstream. To reach and maintain the plasma concentration needed to paralyze the parasite's neuromuscular system, without drifting into a range that stresses the patient's own physiology, the dose has to scale with the volume of tissue it is distributing into. That volume tracks with body weight far more reliably than it tracks with age or with a standardized "adult dose."

The reason ivermectin can paralyze a parasite without similarly paralyzing the human taking it comes down to a specific receptor difference. The drug binds glutamate-gated chloride channels, ion channels found in the nerve and muscle cells of nematodes, insects, and other invertebrates, causing sustained paralysis of the parasite. Mammals, including humans, do not have glutamate-gated chloride channels. Ivermectin does have some affinity for a different receptor type, GABA-gated chloride channels, which humans do possess, but in people with a normal, intact blood-brain barrier, a protein pump called P-glycoprotein actively exports ivermectin out of the central nervous system before it accumulates enough to matter. This is a genuinely elegant piece of biology, and it is the reason ivermectin has an acceptable safety margin at approved doses, while also explaining why overdosing, or using veterinary formulations meant for animals many times a human's body weight, is dangerous: the safety margin depends on staying inside the dose range that biology, not habit, defines.

What the Clinical Evidence Actually Supports, and Where It Runs Out

For strongyloidiasis and onchocerciasis, the evidence base is deep and long-standing: decades of randomized trials and mass drug administration data, including work coordinated through the World Health Organization's onchocerciasis control programs, support both efficacy and a well-characterized safety profile at the doses described above. This is strong, replicated human evidence, not preliminary or in vitro findings.

The picture is different for uses that generated enormous public interest during the COVID-19 pandemic. Early interest was driven partly by an in vitro laboratory study (Monash University, Australia, published in Antiviral Research in 2020) showing that ivermectin reduced viral replication in cell culture, but the concentrations required were far higher than what is safely achievable in human plasma at approved doses. That gap between a petri dish finding and a safe human dose is exactly the kind of distinction that matters and is often lost in translation. Subsequent, larger human trials did not bear out a clinical benefit: the ACTIV-6 trial, a National Institutes of Health-funded randomized controlled trial published in JAMA in 2022, found no significant improvement in recovery time among outpatients with mild-to-moderate COVID-19 treated with ivermectin at doses up to 400 mcg/kg daily for three days, compared to placebo. The TOGETHER trial, a multi-country randomized platform trial (including McMaster University collaborators) published in the New England Journal of Medicine in 2022, similarly found no reduction in hospitalization risk with ivermectin. On the strength of this randomized evidence, the FDA and other regulators have not authorized ivermectin for COVID-19, and that position reflects the trial data rather than institutional reluctance. Readers weighing that history deserve the straightforward version: the laboratory signal was real but did not translate into a human clinical benefit at safe doses, and saying so plainly is more useful than either dismissing the early interest or overstating what it proved.

Practical Safety and the Case for Working With Your Own Physician

Because the correct dose depends on accurate body weight, kidney and liver status, concurrent medications, and the specific parasite being treated, self-calculating a dose from an online chart carries real risk, especially with veterinary ivermectin products, which are formulated at concentrations meant for animals weighing hundreds of pounds and are not held to human pharmaceutical manufacturing standards. Poison control centers in multiple countries documented a rise in ivermectin-related calls during periods of high public interest, generally involving self-dosing or use of animal formulations. Common side effects at approved doses include dizziness, nausea, and diarrhea; more serious reactions are rare but can include low blood pressure and, in patients with certain co-infections such as high-burden loiasis, severe neurological reactions, which is why physicians screen for that specific parasite before treating for onchocerciasis in affected regions. None of this is a reason to fear a properly prescribed medication; it is a reason to get your weight, your diagnosis, and your dose confirmed by a clinician who knows your full medical history, which is exactly the kind of personal, accountable care that protects both the patient and the family depending on that patient staying well.

Key takeaway: Ivermectin's dose is calculated from your body weight and the specific parasitic condition being treated, not read off a generic chart, and its strong track record belongs to those approved parasitic uses rather than to unproven applications.